Skip to Content

Calcimar (calcitonin) Disease Interactions

There are 2 disease interactions with Calcimar (calcitonin):

Moderate

Calcitonin (applies to Calcimar) hypocalcemia

Moderate Potential Hazard, High plausibility.

Calcitonin inhibits bone resorption, which results in decreased serum calcium levels. Following single IV doses, a marked transient inhibition of the ongoing bone resorptive process occurs, while continuous use leads to a persistent, smaller decrease in rate of bone resorption. Because of the drug's acute hypocalcemic effects, patients administered calcitonin may, theoretically, experience tetany under certain circumstances. Calcitonin should be administered cautiously to patients with preexisting hypocalcemia, since they may be particularly sensitive to these effects. Hypocalcemia should preferably be corrected prior to initiation of therapy. If calcitonin is used to increase bone mineral density, such as in osteoporosis, an adequate intake of calcium and vitamin D should be ensured throughout the course of treatment.

References

  1. "Product Information. Calcimar (calcitonin)." Rhone-Poulenc Rorer, Collegeville, PA.
  2. "Product Information. Miacalcin Injection, Synthetic (calcitonin)." Novartis Pharmaceuticals, East Hanover, NJ.
Moderate

Calcitonin (applies to Calcimar) mineral metabolism disorders

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Hypocalcemia, Vitamin D Deficiency

When calcitonin is used for the treatment of osteoporosis, hypocalcemia and other disturbances of mineral metabolism such as vitamin D deficiency should be treated prior to initiation of therapy. The desired increase in bone mineral density requires an adequate supply of calcium and vitamin D in the body. In patients with these conditions, serum calcium and symptoms of hypocalcemia should be monitored during therapy with calcitonin salmon nasal spray. Appropriate intake of calcium and vitamin D should be ensured throughout the course of treatment.

References

  1. "Product Information. Calcimar (calcitonin)." Rhone-Poulenc Rorer, Collegeville, PA.
  2. "Product Information. Miacalcin Injection, Synthetic (calcitonin)." Novartis Pharmaceuticals, East Hanover, NJ.

Calcimar (calcitonin) drug interactions

There are 5 drug interactions with Calcimar (calcitonin)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.